Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sha Zhu

Showing results (281-290 of 307) with videos related to

Pageof 31
Sort By:
The Prostate|August 26, 2021
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancerZhipeng Wang, Sha Zhu, Jinge Zhao, et al.
Small (Weinheim an Der Bergstrasse, Germany)|December 8, 2016
Persistency of Enlarged Autolysosomes Underscores Nanoparticle-Induced Autophagy in HepatocytesJi-Qian Zhang, Wei Zhou, Sha-Sha Zhu, et al.
Nature Communications|June 25, 2026
Intravenous administration of an engineered AAV9-gene-silencing vector suppresses human SOD1 and extends survival in an ALS mouse modelFang Wan, Jinchen He, Hong Ma, et al.
The Prostate|May 24, 2021
Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patientsSha Zhu, Junru Chen, Yuchao Ni, et al.
Nature Communications|June 12, 2024
UBE2D3 facilitates NHEJ by orchestrating ATM signalling through multi-level control of RNF168Zeliha Yalçin, Shiu Yeung Lam, Marieke H Peuscher, et al.
Cancer Letters|October 25, 2023
SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrestChong Wang, Tao Wang, Kang-Jing Li, et al.
The Prostate|July 12, 2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapyJinge Zhao, Mengni Zhang, Jiandong Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 8, 2025
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and AdolescentsHaoyang Liu, Haolin Liu, Junru Chen, et al.
ACS Central Science|October 27, 2025
Enzyme Activity-Based Genome-wide Screening for Modifiers of Lysosomal Glucocerebrosidase Uncovers Candidate Risk Factors for Parkinson's DiseaseVinod Udayar, Pierre-André Gilormini, Julien Bryois, et al.
Molecular Cancer|June 26, 2024
Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinomaJunjie Zhao, Yanfeng Tang, Xu Hu, et al.
Pageof 31

Showing results (281-290 of 307) with videos related to

Sort By:
Pageof 31
The Prostate|August 26, 2021
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancerZhipeng Wang, Sha Zhu, Jinge Zhao, et al.
Small (Weinheim an Der Bergstrasse, Germany)|December 8, 2016
Persistency of Enlarged Autolysosomes Underscores Nanoparticle-Induced Autophagy in HepatocytesJi-Qian Zhang, Wei Zhou, Sha-Sha Zhu, et al.
Nature Communications|June 25, 2026
Intravenous administration of an engineered AAV9-gene-silencing vector suppresses human SOD1 and extends survival in an ALS mouse modelFang Wan, Jinchen He, Hong Ma, et al.
The Prostate|May 24, 2021
Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patientsSha Zhu, Junru Chen, Yuchao Ni, et al.
Nature Communications|June 12, 2024
UBE2D3 facilitates NHEJ by orchestrating ATM signalling through multi-level control of RNF168Zeliha Yalçin, Shiu Yeung Lam, Marieke H Peuscher, et al.
Cancer Letters|October 25, 2023
SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrestChong Wang, Tao Wang, Kang-Jing Li, et al.
The Prostate|July 12, 2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapyJinge Zhao, Mengni Zhang, Jiandong Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 8, 2025
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and AdolescentsHaoyang Liu, Haolin Liu, Junru Chen, et al.
ACS Central Science|October 27, 2025
Enzyme Activity-Based Genome-wide Screening for Modifiers of Lysosomal Glucocerebrosidase Uncovers Candidate Risk Factors for Parkinson's DiseaseVinod Udayar, Pierre-André Gilormini, Julien Bryois, et al.
Molecular Cancer|June 26, 2024
Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinomaJunjie Zhao, Yanfeng Tang, Xu Hu, et al.
Pageof 31